High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy
NCT05006937
Recruiting
The purpose of this study is to determine the differences in stone free results, patient side effects, and patient satisfaction between dusting vs. basket extraction for kidney and ureteral stones (a kidney stone located in the tube between the kidney and bladder) 6 mm and greater in size undergoing ureteroscopic treatment. Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine. Basket extraction is when a small wire basket is used to r... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/18/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Kidney Stone, Ureteral Stone
Register for Updates
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona +17 locations
Conditions: Advanced or Metastatic Solid Tumor Malignancies
Register for Updates
Long-term Follow-up of Subjects Treated With CAR T Cells
NCT05024175
Recruiting
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Register for Updates
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)
NCT05070013
Recruiting
Parkinson's Disease (PD) is the second most common of the age-related neurodegenerative disorders, affecting over 1,900 adults per 100,000 over the age of 80 in the US. The prevalence of sleep dysfunction in PD is estimated at nearly 80-90% which includes sleep fragmentation, insomnia, rapid eye movement (REM or dream sleep) Sleep Behavior Disorder (RBD), Restless legs syndrome (RLS), periodic limb movement, excessive daytime sleepiness, and sleep apnea. Sleep is vital to homeostasis, cognition,... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/18/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska +1 locations
Conditions: Parkinson's Disease, Sleep Fragmentation
Register for Updates
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
NCT05100017
Recruiting
Stone disease is a common condition, affecting approximately 9% of Americans in 2007. It causes great morbidity and is also a costly condition, estimated to cost the US healthcare system approximately 3.79 billion dollars in 2007. Ureteroscopy (URS) is the most commonly performed surgical treatment for upper tract stone disease. Ureteral stenting is a common practice after ureteroscopy and placed in \~75% of cases to prevent ureteral edema and renal obstruction. Unfortunately, ureteral stenting... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/18/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Kidney Calculi, Kidney Diseases, Nephrolithiasis, Urolithiasis, Ureteral Diseases, Ureteral Calculi
Register for Updates
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017
Recruiting
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +108 locations
Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Register for Updates
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
NCT05157113
Recruiting
The current postoperative cataract surgery eye drop regimen used at Zuckerberg San Francisco General Hospital (ZSFG) is a significant burden for its patient population, contributing to high rates of non-adherence and the development of postoperative complications. The investigators propose to replace this complex regimen with a single administration of intraocular antibiotic and subconjunctival steroid at the time of surgery. This pilot study will obtain the preliminary data required to eventual... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG), San Francisco, California
Conditions: Cataract, Surgery, Compliance, Patient, Compliance, Medication, Satisfaction, Patient
Register for Updates
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
NCT05318469
Recruiting
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab or pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Register for Updates
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT05360160
Recruiting
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL). Part 2 of this study is to learn if the dose of study drugs found in Part 1b can help to control AML/MPAL
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/18/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)
NCT05375162
Recruiting
The purpose of the present study is to utilize Multiphase Optimization Strategy (MOST)1 to test four social support and mindfulness components (e-coaching, buddy, general mindfulness training, and MVPA-specific mindfulness training) in a 12-week mHealth moderate to vigorous intensity physical activity (MVPA) intervention in a sample of young adult cancer survivors (YACS), to improve quality of life (QOL) and decrease adverse effects and symptom burden. PRIMARY AIM To identify which components f... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/18/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Cancer
Register for Updates
My Best GI Eating Study
NCT05396846
Recruiting
The MyBestGI study evaluates three different approaches that could help people eat in healthier ways. The study seeks to enroll 240 overweight and obese persons who have risk factors for colorectal cancers such as a family or personal history of colorectal cancers or adenomatous polyps. The study website is www.MyBestGI.org . Participants in the study will be asked to follow one of three eating plans, as best they can, for 12 months. Study participants can choose the foods they prefer within he... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/18/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Colorectal Neoplasms
Register for Updates
Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis
NCT05440214
Recruiting
People with psychotic disorders are excluded from most suicide-focused clinical trials despite incredibly high rates of completed suicide, and interventions that have been tested for this population have shown limited impact on suicide. Emotion dysregulation is a significant suicidogenic factor that is understudied in people with psychotic disorders. The investigators propose to implement and evaluate an intervention targeting emotion dysregulation in people with psychotic disorders while employ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Psychosis, Suicide
Register for Updates